Literature DB >> 11174386

Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema.

F Rongioletti1, A Rebora.   

Abstract

Lichen myxedematosus (LM) is an idiopathic cutaneous mucinosis; its classification dates back to 1953, when Montgomery and Underwood distinguished 4 types of LM: a generalized lichenoid eruption, later called scleromyxedema, a discrete papular form, a localized or generalized lichenoid plaque form, and an urticarial plaque form. In the literature, the terms LM, papular mucinosis, and scleromyxedema have been often used indiscriminately as synonyms, but most reported cases of LM or papular mucinosis without indication of the subtype appear in fact to be cases of scleromyxedema. On the basis of personal experience, the anatomoclinical manifestations of published cases of LM, papular mucinosis, and scleromyxedema are reviewed to distinguish clearly between a generalized form with systemic, even lethal, manifestations and a localized form, which does not run a disabling course. LM includes two clinicopathologic subsets: a generalized papular and sclerodermoid form (also called scleromyxedema) and a localized papular form. Diagnosis of scleromyxedema should fulfill the following criteria: (1) generalized papular and sclerodermoid eruption; (2) mucin deposition, fibroblast proliferation, and fibrosis; (3) monoclonal gammopathy; and (4) the absence of thyroid disease. The criteria for localized LM are as follows: (1) papular or nodular/plaque eruption; (2) mucin deposition with variable fibroblast proliferation; and (3) the absence of both monoclonal gammopathy and thyroid disease. The localized form is subdivided into 5 subtypes: (1) a discrete papular form involving any site; (2) acral persistent papular mucinosis involving only the extensor surface of the hands and wrists; (3) self-healing papular mucinosis, of a juvenile and an adult type; (4) papular mucinosis of infancy, a pediatric variant of the discrete form or of acral persistent papular mucinosis; and (5) nodular form. A third group of atypical or intermediate forms, not meeting the criteria for either scleromyxedema or the localized form, includes cases of (1) scleromyxedema without monoclonal gammopathy, (2) localized forms with monoclonal gammopathy and/or systemic symptoms, (3) localized forms with mixed features of the 5 subtypes, and (4) not well-specified cases.

Entities:  

Mesh:

Year:  2001        PMID: 11174386     DOI: 10.1067/mjd.2001.111630

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  50 in total

Review 1.  Update on systemic sclerosis.

Authors:  Courtney J McCray; Maureen D Mayes
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

Review 2.  Follicular mucinosis in patients with hematologic malignancies other than mycosis fungoides: A clinicopathologic study.

Authors:  Shamir Geller; Christian J Gomez; Patricia L Myskowski; Melissa Pulitzer
Journal:  J Am Acad Dermatol       Date:  2019-02-01       Impact factor: 11.527

3.  [Scleromyxedema. A chronic progressive systemic disease].

Authors:  A Kreuter; M Stücker; A G A Kolios; P Altmeyer; K Möllenhoff
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

Review 4.  [Scleromyxedema].

Authors:  M Neufeld; C Sunderkötter; R K C Moritz
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

5.  Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation.

Authors:  Michele L Donato; Adrienne M Feasel; Donna M Weber; Victor G Prieto; Sergio A Giralt; Richard E Champlin; Madeleine Duvic
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

Review 6.  Scleroderma mimics.

Authors:  Jennifer Nashel; Virginia Steen
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 7.  Self-healing juvenile cutaneous mucinosis, a sclerodermoid disorder simulating juvenile dermatomyositis: a case-based review.

Authors:  Anuradha Bishnoi; Ankur Kumar Jindal; Gummadi Anjani; Pratap Kumar Patra; Debajyoti Chatterjee; Keshavamurthy Vinay; Amrinder J Kanwar; Sunil Dogra; Surjit Singh
Journal:  Rheumatol Int       Date:  2020-04-22       Impact factor: 2.631

8.  Plaque-Like Sclerodermiform Localized Mucinosis Rapidly Responsive to Topical Tacrolimus.

Authors:  R Schmaltz; T Vogt; C S L Müller
Journal:  Case Rep Dermatol       Date:  2010-09-01

Review 9.  [Scleroderma and fibrosing diseases].

Authors:  U A Walker; P Knöss; M Jakobs; V Krenn
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

10.  Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy.

Authors:  Julie Delyon; Maud Bézier; Michel Rybojad; Josette Brière; Pierre Validire; Martine Bagot; Anne Janin; Maxime Battistella
Journal:  Virchows Arch       Date:  2013-05-17       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.